Neal Muni appointed chief executive of CutisPharma

US specialty pharma company CutisPharma has appointed Neal Muni as chief executive officer.

He moves from his role as president and replaces Indu Muni, who founded the company in 1998, and who will remain chairman of the board. Dr Muni has been the company’s president since July 2014 and has successfully led the development and execution of operational and commercial projects. He previously served as executive director of new product planning at Sunovion Pharmaceuticals.

Dr Muni said: "I am excited to build on CutisPharma's impressive growth trajectory and to lead the company as it pursues its long-term strategic vision of transforming compounding through innovation. There are significant needs for high quality and solid science in pharmaceutical compounding, and our company's mission over its 17 years of operation has been to provide patients with better solutions based first and foremost on quality. As recent events demonstrate all too well, the consequences of poor quality in compounded products can be tragic. Our goal from day one has been to follow the best science and manufacturing standards to help pharmacists provide high quality and safe compounded products. Further, we have aimed to do this in a manner that is cost-effective and facilitates better control of compounding utilization by our managed care partners."